Gene therapy ethics and haemophilia: an inevitable therapeutic future?
about
Gene therapy of monogenic and cardiovascular disorders.Incorporation of DOPE into Lipoplexes formed from a Ferrocenyl Lipid leads to Inverse Hexagonal Nanostructures that allow Redox-Based Control of Transfection in High Serum.Staunch protections: the ethics of haemophilia gene transfer research.Ethical considerations in clinical investigation: exploring relevance in haemophilia research.Clinical advances in hemophilia management.Gene therapy for hemophilia? No.
P2860
Gene therapy ethics and haemophilia: an inevitable therapeutic future?
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Gene therapy ethics and haemophilia: an inevitable therapeutic future?
@ast
Gene therapy ethics and haemophilia: an inevitable therapeutic future?
@en
type
label
Gene therapy ethics and haemophilia: an inevitable therapeutic future?
@ast
Gene therapy ethics and haemophilia: an inevitable therapeutic future?
@en
prefLabel
Gene therapy ethics and haemophilia: an inevitable therapeutic future?
@ast
Gene therapy ethics and haemophilia: an inevitable therapeutic future?
@en
P2093
P2860
P921
P1433
P1476
Gene therapy ethics and haemophilia: an inevitable therapeutic future?
@en
P2093
P2860
P304
P356
10.1046/J.1365-2516.2003.00725.X
P577
2003-03-01T00:00:00Z